VERUVeruVERU info
$0.80info3.26%24h
Global rank20413
Market cap$116.32M
Change 7d-8.61%
YTD Performance7.45%
SP500 benchmarkUnderperform
P/E0
P/S7.14
Revenue$16.30M
Earnings-$93.09M
Dividend yield-
Main Sector
Healthcare

Veru (VERU) Stock Overview

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Stock Information

Symbol
VERU
Address
2916 North Miami AvenueMiami, FL 33127United States
Founded
-
Trading hours
-
Website
https://verupharma.com
Country
πŸ‡ΊπŸ‡Έ United States
Phone Number
305 509 6897

Veru (VERU) Price Chart

-
Value:-

Veru Overview: Key Details and Summary

Stock data
2023
Change
Price
$0.7951
N/A
Market Cap
$116.32M
N/A
Shares Outstanding
146.29M
82.58%
Employees
189.00
N/A
Shareholder Equity
17.78M
-78.00%
Valuation
2023
Change
P/S Ratio
7.14
N/A
P/B Ratio
6.54
N/A
Growth
2023
Change
Return on Equity
-5.2347
N/A
Earnings
2023
Change
Revenue
$16.30M
N/A
Earnings
-$93.09M
N/A
Gross Margin
0.4643
N/A
Operating Margin
-5.86
N/A
Net income margin
-5.71
N/A
Financial Strength
2023
Change
Total Assets
$50.60M
N/A
Total Debt
$14.41M
N/A
Cash on Hand
$9.63M
N/A
Debt to Equity
$1.85
169.79%
Cash to Debt
0.6682
-86.77%
Current Ratio
$1.16
-54.15%
logo
Facebook Icon
Twitter Icon
Linkedin Icon
Β© 2024 Topstocks.org